Professor John Luong
John has been with National Research Council of Canada since 1983. He is Principal Research Officer and Leader of the Biosensors and Nanobiotechnology Group at the NRC Biotechnology Research Institute (BRI).He obtained a Ph.D. in Chemical/Biochemical Engineering from McGill University in 1979, and worked four years as a research engineer for a large Canadian food/specialty chemical company before joining BRI. He has also acted as visiting professor of Chemical Engineering at McGill University and is currently adjunct professor of Chemical Engineering at the University of Waterloo.
His research interests include nanostructure-based biosensors, probing cell behavior by impedance spectroscopy, labs-on-chips, fabrication and bioanalytical application of nanoparticles and carbon nanotubes.
He has 5 patents to his credit, and several other patents pending, has published over 200 scientific articles and has served on the editorial board of several international journals. He has received several awards for research excellence.
Dr Andrew Whitehead
Dr Whitehead is currently the Director of 2nd Generation, GSK in Cork.
Dr Whitehead has had a distinguished career in the pharmaceutical industry with a strong track record of scientific and technical achievement in addition to leadership within the industry. His CV highlights his many achievements and markers of recognition including the Presidents Roll of Honour Award in GMS and most recently his selection within GSK R&D to be given the opportunity to act as an adjunct professor in UCC, an opportunity which is available to just a very limited group of scientists within GSK.
His experience and insight into medicinal and pharmaceutical chemistry is particularly valuable as a resource for the postgraduate students within the ABCRF and indeed within the SFI Centre focused on the Synthesis and Solid State Pharmaceuticals Centre (SSPC), led by UL; the UCC elements of the SSPC are based in the ABCRF. It is envisaged that he will develop a postgraduate module focused specifically on the industrial aspects of medicinal and pharmaceutical chemistry. This will prove very beneficial to the early career researchers in providing them with a background for future careers in the pharmaceutical industry. In addition the academic staff in the ABCRF will benefit from exposure to his insights into current challenges in the pharmaceutical industry and will be in a position to leverage this in research proposals (in the current context where industrial relevance is a key success factor) and in their undergraduate teaching with clear benefit to the university.